<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-148071" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Kratom</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jentsch</surname>
            <given-names>Maxwell J.</given-names>
          </name>
          <aff>Sanford Medical Center Fargo</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pippin</surname>
            <given-names>Micah M.</given-names>
          </name>
          <aff>LSUHSC Shreveport</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Maxwell Jentsch declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Micah Pippin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-148071.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Kratom (Mitragyna speciosa) is a plant indigenous to Southeast Asia, typically consumed by tea or powder, with physiologic effects similar to opioids, as well as stimulants. There is an increasing prevalence of kratom use, raising concern for possible dependence, addiction, and toxicity. Given the increasing popularity and the potential harm this substance could cause, it is essential to understand how it works, its physiologic side effects, and any possible treatment options for symptoms related to a toxic overdose. This activity reviews the etiology, presentation, evaluation, and management/prevention of kratom toxicity and also reviews the role of the interprofessional team with management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the pathophysiology/toxicokinetics of kratom toxicity.</p></list-item><list-item><p>Outline the signs, symptoms, and examination findings for patients with kratom toxicity.</p></list-item><list-item><p>Describe management strategies for kratom toxicity.</p></list-item><list-item><p>Review the interprofessional team approach to identifying and improving care for managing patients suffering from kratom toxicity.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=148071&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=148071">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-148071.s2" sec-type="Indications">
        <title>Indications</title>
        <p>With the rise in patients taking naturalistic approaches to healthcare, it is crucial to be aware of kratom and the risks associated with its ingestion.<xref ref-type="bibr" rid="article-148071.r1">[1]</xref> Kratom (<italic toggle="yes">Mitragyna speciosa</italic>) is a plant indigenous to southeastern Asia, typically consumed as tea or powder, with physiologic effects similar to opioids and stimulants. The use of kratom in southeastern Asia has been common for the past few centuries, but it is gaining popularity in the West.<xref ref-type="bibr" rid="article-148071.r2">[2]</xref>&#x000a0;As there is an increasing prevalence of kratom use, there is also increasing&#x000a0;concern for possible dependence, addiction, and toxicity.<xref ref-type="bibr" rid="article-148071.r3">[3]</xref>&#x000a0;Given the increasing popularity and the potential harm this substance could cause, it is essential to understand how it&#x000a0;works, its physiologic side effects, and any possible treatment options&#x000a0;for symptoms related to a toxic overdose.</p>
        <p>Traditional use of kratom consisted of&#x000a0;remedies for treating symptoms of opiate addiction and withdrawal. Also, it is popular among laborers in rural southeastern Asia for pain relief and fighting off fatigue.<xref ref-type="bibr" rid="article-148071.r3">[3]</xref>&#x000a0;Given the potential for addiction and dependence, it has since been&#x000a0;banned in Malaysia and Thailand.<xref ref-type="bibr" rid="article-148071.r4">[4]</xref>&#x000a0;However, the prevalence of kratom use has increased in the United States, where it is typically used as a recreational drug. From 2011 to 2017, there were over 1800 calls to poison control centers for kratom ingestions, with the majority of those calls occurring in the last two years, indicating a rapid increase in use.<xref ref-type="bibr" rid="article-148071.r5">[5]</xref>&#x000a0;</p>
        <p>The primary motivation for kratom use varies, but some patients with opioid dependence resort to other methods of self-medication, with kratom being an inexpensive alternative. The Drug Enforcement Administration does not recognize kratom as a controlled substance. Thus, it is not subject to the United States Controlled Substances Act, so there is little regulatory oversight regarding the substance's purity, potency, and safety.<xref ref-type="bibr" rid="article-148071.r3">[3]</xref><xref ref-type="bibr" rid="article-148071.r6">[6]</xref> As kratom is an unregulated substance, it is difficult to ascertain the actual concentration of mitragynine, the most prevalent substance in kratom, which can put patients at risk for the potential dangers of the substance.</p>
      </sec>
      <sec id="article-148071.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Kratom has only four known pharmacologically active compounds.<xref ref-type="bibr" rid="article-148071.r7">[7]</xref>&#x000a0;Of these active compounds, mitragynine is the most prevalent, but 7-OH-mitragynine is more pharmacologically&#x000a0;active.<xref ref-type="bibr" rid="article-148071.r8">[8]</xref>&#x000a0;Also, 7-OH-mitragynine is an oxidized metabolite of mitragynine.<xref ref-type="bibr" rid="article-148071.r9">[9]</xref>&#x000a0;Mitragynine is hepatically metabolized to 7-OH-mitragynine.<xref ref-type="bibr" rid="article-148071.r3">[3]</xref>&#x000a0;Compared to morphine, 7-OH-mitragynine has about 13 times the affinity for opioid receptors. 7-OH-mitragynine has about 46 times the affinity for opioid receptors compared to mitragynine.<xref ref-type="bibr" rid="article-148071.r10">[10]</xref><xref ref-type="bibr" rid="article-148071.r11">[11]</xref>&#x000a0;Some studies suggest mitragynine is an agonist at the mu&#x000a0;and delta&#x000a0;receptors, while&#x000a0;7-OH-mitragynine targets the mu and kappa&#x000a0;receptors, although&#x000a0;some studies argue that both act as partial agonists at the mu and delta receptors.<xref ref-type="bibr" rid="article-148071.r11">[11]</xref><xref ref-type="bibr" rid="article-148071.r12">[12]</xref><xref ref-type="bibr" rid="article-148071.r13">[13]</xref>&#x000a0;</p>
        <p>The half-life of mitragynine has an estimated half-life of 3 hours.<xref ref-type="bibr" rid="article-148071.r14">[14]</xref>&#x000a0;When ingested orally, there appears to be linear pharmacokinetics with biphasic elimination.<xref ref-type="bibr" rid="article-148071.r15">[15]</xref>&#x000a0;It remains unclear as to the specific mechanism these&#x000a0;metabolites&#x000a0;have at certain receptors; also, the wide variety of kratom alkaloids and their potential pharmacologic properties make assessing its net physiologic effects challenging.<xref ref-type="bibr" rid="article-148071.r16">[16]</xref><xref ref-type="bibr" rid="article-148071.r17">[17]</xref>&#x000a0;</p>
        <p>One of the important differences between opioids and the alkaloids in kratom is that they are pharmacologically and structurally different. Like opioids, the alkaloids from kratom initiate G-protein-coupled receptors (GPCR) signaling; however, the major difference is that the kratom alkaloids don't initiate the beta-arrestin pathway.<xref ref-type="bibr" rid="article-148071.r18">[18]</xref>&#x000a0;This is important because the beta-arrestin pathway is responsible for some of the adverse symptomatology seen in opioid use, including&#x000a0;respiratory depression, sedation, and constipation.<xref ref-type="bibr" rid="article-148071.r18">[18]</xref><xref ref-type="bibr" rid="article-148071.r19">[19]</xref>&#x000a0;Given the selective nature of kratom alkaloids and the inactivation of the beta-arrestin pathway, kratom makes a promising substance for pain management.&#x000a0;</p>
      </sec>
      <sec id="article-148071.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Given the current opioid epidemic, physicians are encouraged to avoid overprescribing opioids for pain management. However, patients who develop an opioid dependence may resort to alternatives, like kratom, as their opioid prescriptions become&#x000a0;more difficult to obtain. Kratom&#x000a0;has been used by some patients wishing to self-medicate for health conditions associated with chronic pain, where it has been seen as an inexpensive, legal option.<xref ref-type="bibr" rid="article-148071.r20">[20]</xref>&#x000a0;As the Food and Drug Administration&#x000a0;does not regulate kratom, it is ingested in many ways by patients, although it&#x000a0;is typically ingested after the leaves are crushed and then either smoked, brewed in tea, or placed in capsules for ingestion. As kratom has a wide variety of alkaloids, and their potential pharmacologic properties vary, it is difficult to assess the drug's net physiologic effect.<xref ref-type="bibr" rid="article-148071.r16">[16]</xref><xref ref-type="bibr" rid="article-148071.r17">[17]</xref>&#x000a0;</p>
        <p>When ingested orally, there appears to be linear pharmacokinetics with biphasic elimination.<xref ref-type="bibr" rid="article-148071.r15">[15]</xref>&#x000a0;The half-life of mitragynine, one of the more prevalent active compounds in kratom, has an estimated half-life of 3 hours.<xref ref-type="bibr" rid="article-148071.r14">[14]</xref>&#x000a0;An important factor regarding its metabolism is that mitragynine is converted via hepatic metabolism into 7-OH-mitragynine.<xref ref-type="bibr" rid="article-148071.r21">[21]</xref>&#x000a0;This is important as 7-OH-mitragynine is thought to be a&#x000a0;more metabolically active metabolite, leading to most of the effects that kratom produces.<xref ref-type="bibr" rid="article-148071.r21">[21]</xref>&#x000a0;Given the variety of ways kratom is ingested,&#x000a0;more research needs to be done to determine if the way this substance is ingested plays a role in determining overall physiologic side effects.&#x000a0;</p>
      </sec>
      <sec id="article-148071.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Kratom and its metabolites can cause a variety of symptoms, including neurologic, metabolic, and psychological symptoms. A study by the National Poison Data system in 2019 found that the most common presenting symptoms after kratom ingestion included agitation, tachycardia, drowsiness, and confusion.<xref ref-type="bibr" rid="article-148071.r22">[22]</xref>&#x000a0;As many patients with chronic pain, or a history of opioid dependence, turn to alternatives for managing their symptoms, kratom has become a popular choice; however, given this substance is unregulated, it has the potential for patients to develop dependence, addiction, and toxicity.<xref ref-type="bibr" rid="article-148071.r13">[13]</xref>&#x000a0;</p>
        <p>Multiple organ systems are at risk for potential injury due to&#x000a0;kratom ingestion. Multiple case studies have found a range of toxicities and adverse events associated with&#x000a0;kratom use, including hepatotoxicity, seizure and coma, lung injury, kidney injury, and cardiotoxicity.<xref ref-type="bibr" rid="article-148071.r23">[23]</xref>&#x000a0;Pregnant patients who use kratom have an additional risk of their newborns developing neonatal abstinence syndrome.<xref ref-type="bibr" rid="article-148071.r24">[24]</xref><xref ref-type="bibr" rid="article-148071.r25">[25]</xref><xref ref-type="bibr" rid="article-148071.r26">[26]</xref>&#x000a0;Long-term cognitive impairment has also been seen in those with chronic kratom use.<xref ref-type="bibr" rid="article-148071.r27">[27]</xref>&#x000a0;In some cases, kratom toxicity&#x000a0;has also been linked to death.<xref ref-type="bibr" rid="article-148071.r28">[28]</xref>&#x000a0;It is also important to remember that kratom is an unregulated substance, so the potential for tampering&#x000a0;makes it potentially dangerous. Also, patients with a history of polysubstance abuse&#x000a0;are predisposed to kratom&#x000a0;toxicity and death.<xref ref-type="bibr" rid="article-148071.r29">[29]</xref></p>
      </sec>
      <sec id="article-148071.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There is little information regarding absolute contraindications for kratom use; however, there is a risk of possible pharmacologic&#x000a0;interactions for patients who&#x000a0;ingest it. Mitragynine, a substrate of kratom,&#x000a0;appears to inhibit glucuronidation by UDP-glucuronosyltransferases (UGT).<xref ref-type="bibr" rid="article-148071.r30">[30]</xref>&#x000a0;This interaction is important as possible co-ingestions with other drugs with known UGT substrates, like buprenorphine or ketamine, can contribute to toxicities and lead to fatal supratherapeutic levels of drugs and their substrates.<xref ref-type="bibr" rid="article-148071.r31">[31]</xref><xref ref-type="bibr" rid="article-148071.r32">[32]</xref>&#x000a0;Therefore, it is likely best for patients who take medications metabolized by UGT to avoid kratom use or consult their clinician before using kratom.&#x000a0;</p>
        <p>Also, patients with liver, neurologic, pulmonary, renal, or cardiac disease should avoid this substance as there have been multiple case studies showing that kratom can potentially cause injury&#x000a0;to these organ systems.<xref ref-type="bibr" rid="article-148071.r23">[23]</xref>&#x000a0;It is also best for pregnant patients to avoid kratom use due to the potential for newborns to develop&#x000a0;neonatal abstinence syndrome.<xref ref-type="bibr" rid="article-148071.r25">[25]</xref><xref ref-type="bibr" rid="article-148071.r26">[26]</xref>&#x000a0;The unregulated status of this substance&#x000a0;makes it difficult to ascertain the actual concentration of its active metabolites, making kratom ingestion potentially harmful. Patients with a history of polysubstance abuse should also attempt to avoid this substance, as polysubstance abuse&#x000a0;is a risk factor linked to kratom-related deaths.<xref ref-type="bibr" rid="article-148071.r29">[29]</xref></p>
      </sec>
      <sec id="article-148071.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>As most patients who present after kratom ingestion will be first seen in the emergency department, it is best for healthcare providers to focus on the patient's airway, breathing, circulation, neurologic status, and initial resuscitation. As these patients can present with various symptoms, it is best to keep a broad differential. Labwork and imaging can vary based on the patient's presentation. If kratom toxicity is suspected or known, it is also important, and likely beneficial, for providers to consult their local poison control center early in managing patients to help guide monitoring, treatment, and patient disposition.&#x000a0;</p>
        <p>Monitoring and screening patients for&#x000a0;suspected kratom ingestion can be complex, as it does not typically appear on routine drug screens. Presentation for kratom toxicity can differ as symptoms can vary based on the dose administered and whether the ingested kratom had been altered. The physiologic effects of kratom ingestion vary based on a dose-dependent manner,&#x000a0;where stimulant-like effects are seen at lower doses, and opioid-like effects are seen at higher doses.<xref ref-type="bibr" rid="article-148071.r16">[16]</xref><xref ref-type="bibr" rid="article-148071.r17">[17]</xref>&#x000a0;Toxicities typically occur when the ingested dose exceeds 8 grams.<xref ref-type="bibr" rid="article-148071.r22">[22]</xref>&#x000a0;There are no specific guidelines on the length of time patients need to be monitored, but mitragynine, one of the major substrates of kratom, has a reported&#x000a0;half-life of 3 hours.<xref ref-type="bibr" rid="article-148071.r14">[14]</xref></p>
        <p>After kratom ingestion, a patient's presenting symptoms can help guide evaluation, work-up, and management. Multiple organ systems are at risk for potential injury after kratom ingestion. Multiple case studies have found a range of toxicities and issues due to kratom, including hepatotoxicity, seizure and coma, lung injury, kidney injury, and cardiotoxicity.<xref ref-type="bibr" rid="article-148071.r23">[23]</xref>&#x000a0;Pregnant patients who use kratom have an additional risk of newborns developing neonatal abstinence syndrome.<xref ref-type="bibr" rid="article-148071.r24">[24]</xref><xref ref-type="bibr" rid="article-148071.r25">[25]</xref><xref ref-type="bibr" rid="article-148071.r26">[26]</xref>&#x000a0;Long-term cognitive impairment has also been seen in those with chronic kratom use.<xref ref-type="bibr" rid="article-148071.r27">[27]</xref>&#x000a0;In some cases, kratom toxicity&#x000a0;has been linked to death.<xref ref-type="bibr" rid="article-148071.r28">[28]</xref>&#x000a0;It is also important to remember that kratom is an unregulated substance, so the potential for tampering&#x000a0;makes it potentially dangerous. Also, given its unregulated status, patients with polysubstance abuse predispose patients to toxicity and death.<xref ref-type="bibr" rid="article-148071.r29">[29]</xref></p>
      </sec>
      <sec id="article-148071.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>As many patients with kratom toxicity will primarily be seen in the emergency department, performing a primary survey and assessing the patient's airway, breathing, and circulation is crucial. Developing a broad differential in these patients is imperative as initial presenting symptoms may vary based on the dose of kratom ingested. Also, screening for kratom misuse is primarily based on patient disclosure, as kratom is not detected on regular drug screens.</p>
        <p>There are no formal, evidence-based guidelines for the treatment of kratom toxicity. Presentations for kratom toxicity can differ as symptoms vary based on the dose ingested and whether the substance has been altered. The physiologic effects of kratom ingestion vary dose-dependently, where stimulant-like effects are seen at lower doses, and opioid-like effects are seen at higher doses.<xref ref-type="bibr" rid="article-148071.r16">[16]</xref><xref ref-type="bibr" rid="article-148071.r17">[17]</xref>&#x000a0;Toxicities typically occur when the ingested dose exceeds 8 grams.<xref ref-type="bibr" rid="article-148071.r22">[22]</xref>&#x000a0;Multiple organ systems are at risk for injuries related to kratom use, with hepatotoxicity, seizure and coma, lung injury, kidney injury, and cardiotoxicity&#x000a0;being reported. For pregnant patients who use kratom, there is also the risk of neonates developing neonatal abstinence syndrome.<xref ref-type="bibr" rid="article-148071.r33">[33]</xref><xref ref-type="bibr" rid="article-148071.r25">[25]</xref><xref ref-type="bibr" rid="article-148071.r26">[26]</xref>&#x000a0;Evaluation should be tailored toward the patient's presenting symptoms. Also, it is likely beneficial for providers to contact their local poison control center to help for guidance and assistance if kratom ingestion is suspected or known.&#x000a0;</p>
        <p>At higher doses, kratom toxicity can mimic an opioid toxidrome. While there are reversal agents, like naloxone, for opioid overdoses, the efficacy of reversal agents has not been well established with kratom toxicity. However, there are cases that have reported potential benefits, and some studies have recommended their use.<xref ref-type="bibr" rid="article-148071.r34">[34]</xref><xref ref-type="bibr" rid="article-148071.r35">[35]</xref>&#x000a0;There have also been cases of kratom toxicity causing acute drug-induced hepatitis, in which treatment with&#x000a0;<italic toggle="yes">N</italic>-acetylcysteine has been used, as in&#x000a0;other cases of drug-induced hepatitis.<xref ref-type="bibr" rid="article-148071.r36">[36]</xref>&#x000a0;Standard seizure management with anti-epileptics is warranted for patients who develop seizures after kratom ingestion.<xref ref-type="bibr" rid="article-148071.r33">[33]</xref></p>
      </sec>
      <sec id="article-148071.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Kratom ingestion and toxicity require an interprofessional approach. Depending on the severity of presenting symptoms, critical care, nursing, pharmacy, social work, and addiction services may be required. Nursing and pharmacy are essential for the initial resuscitation and delivery of medications. Pharmacists, in particular, need to be knowledgeable about the effects of this substance so they can inform patients and other interprofessional healthcare team members&#x000a0;regarding kratom use. Critical care teams and psychiatry involvement is crucial for critically ill patients with possible co-ingestions and those with suicidal intent. Social work and addiction services are necessary for those motivated to control their drug addiction. Overall, kratom use, toxicity, and withdrawal require further research to develop definitive management practices.</p>
      </sec>
      <sec id="article-148071.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=148071&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=148071">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/148071/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=148071">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-148071.s11">
        <title>References</title>
        <ref id="article-148071.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Grundmann</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>McCurdy</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Garcia-Romeu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schriefer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Swogger</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Kratom use as more than a "self-treatment".</article-title>
            <source>Am J Drug Alcohol Abuse</source>
            <year>2022</year>
            <month>Nov</month>
            <day>02</day>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>684</fpage>
            <page-range>684-694</page-range>
            <pub-id pub-id-type="pmid">35767669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jansen</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Prast</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Ethnopharmacology of kratom and the Mitragyna alkaloids.</article-title>
            <source>J Ethnopharmacol</source>
            <year>1988</year>
            <season>May-Jun</season>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>115</fpage>
            <page-range>115-9</page-range>
            <pub-id pub-id-type="pmid">3419199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eastlack</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Cornett</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Kratom-Pharmacology, Clinical Implications, and Outlook: A Comprehensive Review.</article-title>
            <source>Pain Ther</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-69</page-range>
            <pub-id pub-id-type="pmid">31994019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cinosi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Martinotti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Simonato</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Demetrovics</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Roman-Urrestarazu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bersani</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Vicknasingam</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Piazzon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Kapit&#x000e1;ny-F&#x000f6;v&#x000e9;ny</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Farkas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Di Giannantonio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Corazza</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Following "the Roots" of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries.</article-title>
            <source>Biomed Res Int</source>
            <year>2015</year>
            <volume>2015</volume>
            <fpage>968786</fpage>
            <pub-id pub-id-type="pmid">26640804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Post</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Spiller</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Chounthirath</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Kratom exposures reported to United States poison control centers: 2011-2017.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>57</volume>
            <issue>10</issue>
            <fpage>847</fpage>
            <page-range>847-854</page-range>
            <pub-id pub-id-type="pmid">30786220</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tobacyk</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Parks</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Lovelady</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brents</surname>
                <given-names>LK</given-names>
              </name>
            </person-group>
            <article-title>Qualitative content analysis of public responses to an FDA inquiry on the impact of scheduling changes to kratom.</article-title>
            <source>Int J Drug Policy</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>108</volume>
            <fpage>103817</fpage>
            <pub-id pub-id-type="pmid">35952436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takayama</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa.</article-title>
            <source>Chem Pharm Bull (Tokyo)</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>52</volume>
            <issue>8</issue>
            <fpage>916</fpage>
            <page-range>916-28</page-range>
            <pub-id pub-id-type="pmid">15304982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shellard</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>The alkaloids of Mitragyna with special reference to those of Mitragyna speciosa, Korth.</article-title>
            <source>Bull Narc</source>
            <year>1974</year>
            <season>Apr-Jun</season>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>41</fpage>
            <page-range>41-55</page-range>
            <pub-id pub-id-type="pmid">4607551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kruegel</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Grundmann</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse.</article-title>
            <source>Neuropharmacology</source>
            <year>2018</year>
            <month>May</month>
            <day>15</day>
            <volume>134</volume>
            <issue>Pt A</issue>
            <fpage>108</fpage>
            <page-range>108-120</page-range>
            <pub-id pub-id-type="pmid">28830758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamamoto</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Horie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Takayama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aimi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sakai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pang</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Ponglux</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Opioid receptor agonistic characteristics of mitragynine pseudoindoxyl in comparison with mitragynine derived from Thai medicinal plant Mitragyna speciosa.</article-title>
            <source>Gen Pharmacol</source>
            <year>1999</year>
            <month>Jul</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <page-range>73-81</page-range>
            <pub-id pub-id-type="pmid">10428019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsumoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Horie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ishikawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takayama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aimi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ponglux</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa.</article-title>
            <source>Life Sci</source>
            <year>2004</year>
            <month>Mar</month>
            <day>12</day>
            <volume>74</volume>
            <issue>17</issue>
            <fpage>2143</fpage>
            <page-range>2143-55</page-range>
            <pub-id pub-id-type="pmid">14969718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsumoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hatori</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Murayama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tashima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wongseripipatana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Misawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kitajima</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takayama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Horie</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Involvement of mu-opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-hydroxymitragynine, isolated from Thai herbal medicine Mitragyna speciosa.</article-title>
            <source>Eur J Pharmacol</source>
            <year>2006</year>
            <month>Nov</month>
            <day>07</day>
            <volume>549</volume>
            <issue>1-3</issue>
            <fpage>63</fpage>
            <page-range>63-70</page-range>
            <pub-id pub-id-type="pmid">16978601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsumoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Horie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Takayama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ishikawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aimi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ponglux</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Murayama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Antinociception, tolerance and withdrawal symptoms induced by 7-hydroxymitragynine, an alkaloid from the Thai medicinal herb Mitragyna speciosa.</article-title>
            <source>Life Sci</source>
            <year>2005</year>
            <month>Nov</month>
            <day>19</day>
            <volume>78</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-7</page-range>
            <pub-id pub-id-type="pmid">16169018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trakulsrichai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sathirakul</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Auparakkitanon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Krongvorakul</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sueajai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Noumjad</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sukasem</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wananukul</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of mitragynine in man.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2015</year>
            <volume>9</volume>
            <fpage>2421</fpage>
            <page-range>2421-9</page-range>
            <pub-id pub-id-type="pmid">25995615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Philipp</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Wissenbach</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Zapp</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Metabolism studies of the Kratom alkaloids mitraciliatine and isopaynantheine, diastereomers of the main alkaloids mitragynine and paynantheine, in rat and human urine using liquid chromatography-linear ion trap-mass spectrometry.</article-title>
            <source>J Chromatogr B Analyt Technol Biomed Life Sci</source>
            <year>2011</year>
            <month>May</month>
            <day>01</day>
            <volume>879</volume>
            <issue>15-16</issue>
            <fpage>1049</fpage>
            <page-range>1049-55</page-range>
            <pub-id pub-id-type="pmid">21450536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Babu</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>McCurdy</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>EW</given-names>
              </name>
            </person-group>
            <article-title>Opioid receptors and legal highs: Salvia divinorum and Kratom.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>46</volume>
            <issue>2</issue>
            <fpage>146</fpage>
            <page-range>146-52</page-range>
            <pub-id pub-id-type="pmid">18259963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Narayanan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vicknasingam</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Traditional and non-traditional uses of Mitragynine (Kratom): A survey of the literature.</article-title>
            <source>Brain Res Bull</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>126</volume>
            <issue>Pt 1</issue>
            <fpage>41</fpage>
            <page-range>41-46</page-range>
            <pub-id pub-id-type="pmid">27178014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>V&#x000e1;radi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marrone</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Narayan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Szab&#x000f3;</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Le Rouzic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Grinnell</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Subrath</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Warner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hunkele</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pagirsky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eans</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Medina</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>YX</given-names>
              </name>
              <name>
                <surname>Borics</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pasternak</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Majumdar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit &#x003b2;-Arrestin-2.</article-title>
            <source>J Med Chem</source>
            <year>2016</year>
            <month>Sep</month>
            <day>22</day>
            <volume>59</volume>
            <issue>18</issue>
            <fpage>8381</fpage>
            <page-range>8381-97</page-range>
            <pub-id pub-id-type="pmid">27556704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bohn</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Lefkowitz</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Caron</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice.</article-title>
            <source>J Neurosci</source>
            <year>2002</year>
            <month>Dec</month>
            <day>01</day>
            <volume>22</volume>
            <issue>23</issue>
            <fpage>10494</fpage>
            <page-range>10494-500</page-range>
            <pub-id pub-id-type="pmid">12451149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boyer</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Babu</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Macalino</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Self-treatment of opioid withdrawal with a dietary supplement, Kratom.</article-title>
            <source>Am J Addict</source>
            <year>2007</year>
            <season>Sep-Oct</season>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>352</fpage>
            <page-range>352-6</page-range>
            <pub-id pub-id-type="pmid">17882605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kruegel</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Uprety</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grinnell</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Langreck</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pekarskaya</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Le Rouzic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ansonoff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gassaway</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Pintar</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Pasternak</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Javitch</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Majumdar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sames</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects.</article-title>
            <source>ACS Cent Sci</source>
            <year>2019</year>
            <month>Jun</month>
            <day>26</day>
            <volume>5</volume>
            <issue>6</issue>
            <fpage>992</fpage>
            <page-range>992-1001</page-range>
            <pub-id pub-id-type="pmid">31263758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eggleston</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Stoppacher</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Suen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Marraffa</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Kratom Use and Toxicities in the United States.</article-title>
            <source>Pharmacotherapy</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>39</volume>
            <issue>7</issue>
            <fpage>775</fpage>
            <page-range>775-777</page-range>
            <pub-id pub-id-type="pmid">31099038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ilmie</surname>
                <given-names>MU</given-names>
              </name>
              <name>
                <surname>Jaafar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mansor</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Abdullah</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Subchronic toxicity study of standardized methanolic extract of Mitragyna speciosa Korth in Sprague-Dawley Rats.</article-title>
            <source>Front Neurosci</source>
            <year>2015</year>
            <volume>9</volume>
            <fpage>189</fpage>
            <pub-id pub-id-type="pmid">26136645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kapp</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Auw&#x000e4;rter</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Winkelmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hermanns-Clausen</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Intrahepatic cholestasis following abuse of powdered kratom (Mitragyna speciosa).</article-title>
            <source>J Med Toxicol</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>227</fpage>
            <page-range>227-31</page-range>
            <pub-id pub-id-type="pmid">21528385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murthy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>An unusual cause for neonatal abstinence syndrome.</article-title>
            <source>Paediatr Child Health</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-14</page-range>
            <pub-id pub-id-type="pmid">30792593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mackay</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Abrahams</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Novel case of maternal and neonatal kratom dependence and withdrawal.</article-title>
            <source>Can Fam Physician</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>64</volume>
            <issue>2</issue>
            <fpage>121</fpage>
            <page-range>121-122</page-range>
            <pub-id pub-id-type="pmid">29449242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Narayanan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Vicknasingam</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Y&#x000fc;cel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>ETW</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Mansor</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Cognitive Effects of Kratom (Mitragyna speciosa Korth.) Use.</article-title>
            <source>J Psychoactive Drugs</source>
            <year>2019</year>
            <season>Jan-Mar</season>
            <volume>51</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-27</page-range>
            <pub-id pub-id-type="pmid">30556488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuehn</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Kratom-Related Deaths.</article-title>
            <source>JAMA</source>
            <year>2019</year>
            <month>May</month>
            <day>28</day>
            <volume>321</volume>
            <issue>20</issue>
            <fpage>1966</fpage>
            <pub-id pub-id-type="pmid">31135856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corkery</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Streete</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Claridge</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Goodair</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Papanti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Orsolini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schifano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sikka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>K&#x000f6;rber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hendricks</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Characteristics of deaths associated with kratom use.</article-title>
            <source>J Psychopharmacol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>33</volume>
            <issue>9</issue>
            <fpage>1102</fpage>
            <page-range>1102-1123</page-range>
            <pub-id pub-id-type="pmid">31429622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Azizi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ismail</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mansor</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Mitragyna speciosa Korth leaves extracts induced the CYP450 catalyzed aminopyrine-N-demethylase (APND) and UDP-glucuronosyl transferase (UGT) activities in male Sprague-Dawley rat livers.</article-title>
            <source>Drug Metabol Drug Interact</source>
            <year>2013</year>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>95</fpage>
            <page-range>95-105</page-range>
            <pub-id pub-id-type="pmid">23435185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hughes</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Fatal combination of mitragynine and quetiapine - a case report with discussion of a potential herb-drug interaction.</article-title>
            <source>Forensic Sci Med Pathol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>110</fpage>
            <page-range>110-113</page-range>
            <pub-id pub-id-type="pmid">30498933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Seah</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Koe</surname>
                <given-names>XF</given-names>
              </name>
              <name>
                <surname>Wahab</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Adenan</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Jamil</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Majid</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>In vitro evaluation of cytochrome P450 induction and the inhibition potential of mitragynine, a stimulant alkaloid.</article-title>
            <source>Toxicol In Vitro</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>812</fpage>
            <page-range>812-24</page-range>
            <pub-id pub-id-type="pmid">23274770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelsen</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Lapoint</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hodgman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Aldous</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Seizure and coma following Kratom (Mitragynina speciosa Korth) exposure.</article-title>
            <source>J Med Toxicol</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>424</fpage>
            <page-range>424-6</page-range>
            <pub-id pub-id-type="pmid">20411370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Overbeek</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Munzer</surname>
                <given-names>BW</given-names>
              </name>
            </person-group>
            <article-title>Kratom (Mitragynine) Ingestion Requiring Naloxone Reversal.</article-title>
            <source>Clin Pract Cases Emerg Med</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-26</page-range>
            <pub-id pub-id-type="pmid">30775658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rech</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Donahey</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cappiello Dziedzic</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Greenhalgh</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>New drugs of abuse.</article-title>
            <source>Pharmacotherapy</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>189</fpage>
            <page-range>189-97</page-range>
            <pub-id pub-id-type="pmid">25471045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148071.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mousa</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Sephien</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gutierrez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>O&#x002bc;Leary</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>N-Acetylcysteine for Acute Hepatitis Induced by Kratom Herbal Tea.</article-title>
            <source>Am J Ther</source>
            <year>2018</year>
            <season>Sep/Oct</season>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>e550</fpage>
            <page-range>e550-e551</page-range>
            <pub-id pub-id-type="pmid">28708700</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
